Previous Close | 5.54 |
1-Year Change | 28.24% |
6-Months Change | -47.98% |
3-Months Change | -33.41% |
Moving Avg (50d) | 5.9222 |
Moving Avg (200d) | 8.6961 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.49B |
Beta (3-Years) | 1.85 |
Revenue Growth (ttm) | -92.22% |
Net Profit Margin (ttm) | -19270.71% |
Return On Assets (ttm) | -85.23% |
EPS (ttm) | -0.63 |
PE Ratio (ttm) | -8.79 |
Dividend Yield | % |
Asset Description: | Inovio Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-11 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
4.151 | 4.274 | 4.355 | 4.477 | 4.681 | 4.884 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |